137 related articles for article (PubMed ID: 35151012)
1. Clinical Characteristics and Treatment Outcomes of Mild to Moderate COVID-19 Patients at Tertiary Care Hospital, Al Baha, Saudi Arabia: A Single Centre Study.
Albanghali M; Alghamdi S; Alzahrani M; Barakat B; Haseeb A; Malik JA; Ahmed S; Anwar S
J Infect Public Health; 2022 Mar; 15(3):331-337. PubMed ID: 35151012
[TBL] [Abstract][Full Text] [Related]
2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia.
Alghamdi S; Barakat B; Berrou I; Alzahrani A; Haseeb A; Hammad MA; Anwar S; Sindi AAA; Almasmoum HA; Albanghali M
Antibiotics (Basel); 2021 Mar; 10(4):. PubMed ID: 33807320
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
6. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.
Mutair AA; Shamou J; Alhumaid S; Layqah L; Ahmed GY; Thoyaja K; Mohaini MA; Almahmoud S; Barry M; Khan A; Dhama K; Al-Jamea LH; Woodman A; Rabaan AA
J Infect Public Health; 2022 Apr; 15(4):389-394. PubMed ID: 35299062
[TBL] [Abstract][Full Text] [Related]
7. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.
Bhandari S; Singh A; Sharma R; Rankawat G; Banerjee S; Gupta V; Dube A; Kakkar S; Sharma S; Keswani P; Agrawal A; Tak A; Nawal CL
J Assoc Physicians India; 2020 Jun; 68(6):13-19. PubMed ID: 32610873
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
9. Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study.
Almazrou SH; Almalki ZS; Alanazi AS; Alqahtani AM; Alghamd SM
Saudi Pharm J; 2020 Dec; 28(12):1877-1882. PubMed ID: 33020690
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: A descriptive cross-sectional study.
Al-Omari A; Alhuqbani WN; Zaidi ARZ; Al-Subaie MF; AlHindi AM; Abogosh AK; Alrasheed AK; Alsharafi AA; Alhuqbani MN; Salih S; Alhedaithy MA; Abdulqawi R; Ismail AF; Alhumaid S; Hamdan N; Saad F; Olhaye FA; Eltahir TA; Alomari M; Alshehery M; Yassiri A; Al-Tawfiq JA; Al Mutair A
J Infect Public Health; 2020 Nov; 13(11):1639-1644. PubMed ID: 33004305
[TBL] [Abstract][Full Text] [Related]
11. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and predictors of mortality among COVID-19 patients in Saudi Arabia.
Albalawi O; Alharbi Y; Bakouri M; Alqahtani A; Alanazi T; Almutairi AZ; Alosaimi B; Mubarak A; Choudhary RK; Alturaiki W
J Infect Public Health; 2021 Aug; 14(8):994-1000. PubMed ID: 34153731
[TBL] [Abstract][Full Text] [Related]
14. Clinical, epidemiological, and laboratory characteristics of mild-to-moderate COVID-19 patients in Saudi Arabia: an observational cohort study.
Al Mutair A; Alhumaid S; Alhuqbani WN; Zaidi ARZ; Alkoraisi S; Al-Subaie MF; AlHindi AM; Abogosh AK; Alrasheed AK; Alsharafi AA; Alhuqbani MN; Alhowar NA; Salih S; Alhedaithy MA; Al-Tawfiq JA; Al-Shammari H; Abdulqawi R; Ismail AF; Hamdan N; Saad F; Olhaye FA; Eltahir TA; Rabaan AA; Al-Omari A
Eur J Med Res; 2020 Nov; 25(1):61. PubMed ID: 33239068
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
16. No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19.
Sands K; Wenzel R; McLean L; Korwek K; Roach J; Miller K; Poland RE; Burgess LH; Jackson E; Perlin JB
Int J Infect Dis; 2021 Mar; 104():34-40. PubMed ID: 33359949
[TBL] [Abstract][Full Text] [Related]
17. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 in People with Diabetes: Perspectives from Saudi Arabia.
Robert AA; Al Dawish MA
Curr Diabetes Rev; 2021; 17(6):e111020187810. PubMed ID: 33176657
[TBL] [Abstract][Full Text] [Related]
20. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
